The global antibody drug conjugates market is anticipated to grow at a considerable CAGR during the forecast period. The antibody-drug conjugates are a significant group of highly potent bio-pharmaceutical drugs that are designed as a targeted treatment for the healing of cancer patients.
The increasing prevalence of cancer is pushing the demand for antibody drug conjugates market. For instance, in 2017, in the US, 1,701,315 new cases were reported of cancer, and 599,099 people died due to the same. Every 100,000 people, 438 new cancer cases were reported and 153 people died due to that. In 2020, it was estimated that 1,806,590 new cases of cancer were diagnosed in the US and there were 606,520 mortalities due to the disease.
Browse the full report description of "Global Antibody Drug Conjugates Market By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, and Others), By Technology (Cleavable Linker and Non-cleavable Linker) - Global Industry Share, Growth, Competitive Analysis and Forecast Period 2021-2027" at https://www.omrglobal.com/industry-reports/antibody-drug-conjugates-market
Moreover, the availability of a large product pipeline and the increasing trend of cost-effective and quality cancer treatment are other factors that are driving the global antibody drug conjugates industry.
Market Coverage
o By Application
o By Technology
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key Questions Addressed by the Report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Antibody Drug Conjugates Market Report Segment
By Application
By Technology
Global Antibody Drug Conjugates Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/antibody-drug-conjugates-market